Equal-WT
WhaleScore 2.0
?
CASDIN CAPITAL, LLC
NEW YORK NY
Investment Advisor
Hedge Fund
Activist Investor
Casdin Capital is based out of New York. Casdin Capital is a hedge fund with 8 clients and discretionary assets under management (AUM) of $2,643,698,992 (Form ADV from 2024-03-30). Their last reported 13F filing for Q2 2024 included $1,304,595,899 in managed 13F securities
and a top 10 holdings concentration of 77.35%. Casdin Capital's largest holding is BioLife Solutions Inc with shares held of 8,707,165. Whalewisdom has at least 38 13F filings, 24 13D filings, 40 13G filings, and 21 Form 4 filings
Business Description
Casdin Capital, LLC provides advisory services tailored to the individual needs and investment mandates of their client funds. They adhere to the investment strategy outlined in the private placement memorandum of each client fund, but do not tailor their services to individual investors within those funds. Investors cannot impose restrictions on the types of securities invested in.
Casdin Capital has full investment discretion for their client funds and does not require approval from the funds or their investors for investment decisions. They do not participate in wrap-fee programs and manage 100% of their regulatory assets under management on a discretionary basis. As of December 31, 2023, they had $2,643,698,992 in regulatory assets under management.
Investment Strategy
The investment strategy focuses on achieving superior long-term adjusted total returns by primarily investing in underappreciated companies with innovative business models in the life sciences and healthcare industry. This includes investing in publicly-traded equity or equivalent securities, both long and short, as well as a broad array of other securities. The strategy also involves investing in both public and private companies, with a focus on small to mid-sized issuers in various life sciences and healthcare sub-sectors.
The investment strategy acknowledges the inherent risks associated with any investment approach, emphasizing that past successes do not guarantee future results. The firm recognizes the potential for market risk and the impact of concentrated investments, which can lead to rapid changes in the portfolio value.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2024-06-30
Top Buys (13F)
| Name | % Change |
|---|---|
| SMFR-DEL SEMA4 HOLDINGS CORP | 4.94% |
| SRPT Sarepta Therapeutics | 2.71% |
| ILMN Illumina Inc | 1.31% |
| CTNM Contineum Therapeuti | 0.4% |
| GH Guardant Health Inc | 0.22% |
2024-06-30
Top Sells (13F)
| Name | % Change |
|---|---|
| GPCR Structure Therapeuti | 1.45% |
| ALNY Alnylam Pharmaceutic | 0.81% |
| ABCL AbCellera Biologics | 0.79% |
| RVMD Revolution Medicines | 0.35% |
| GLUE Monte Rosa Therapeut | 0.19% |
2024-06-30
13F Holdings Summary
| Name | $ Change |
|---|---|
| BLFS BioLife Solutions In | 14.3% |
| RVMD Revolution Medicines | 13.11% |
| SRPT Sarepta Therapeutics | 13% |
| LAB Standard BioTools In | 8.68% |
| SMFR-DEL SEMA4 HOLDINGS CORP | 7.07% |
2024-06-30
13F Activity
| Market Value | $1.30b, Prior: $1.35b |
| Inflows (Outflows) as % of Total MV | (-4.7249)% |
| New Purchases | 3 stocks |
| Added To | 8 stocks |
| Sold out of | 2 stocks |
| Reduced holdings in | 4 stocks |
| Top 10 Holdings % | 77.35% |
| Turnover %[1] | 12.5% |
| Turnover Alt %[2] | 3.83% |
| Time Held Top 20 | 9.65 quarters |
| Time Held Top 10 | 6 quarters |
| Time Held All | 9.95 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2024-06-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2024-06-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2024-06-30